- Mixed dyslipidemia. Third portion. Prevention and therapy recommendations2011 | Second Faculty of Medicine
- Mixed dyslipidemia. First portion. Lipid Quartet, atherogenic lipids2011 | Second Faculty of Medicine
- Mixed dyslipidemia. Second portion. Associated diseases like 2 diabetes mellitus type, obesity, cardiovascular disease2011 | Second Faculty of Medicine
- Severe mixed dyslipidemia as a manifestation of hematological disease: case report2019 | Central Library of Charles University, First Faculty of Medicine
- Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma2014 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma2014 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen
- The effect of treatment with fenofibrate on the risk profile of patients with metabolic syndrome and mixed dyslipidemia treated on an outpatient basis2007 | Faculty of Physical Education and Sport
- The effect of treatment with fenofibrate on the risk profile of patients with metabolic syndrome and mixed dyslipidemia treated on an outpatient basis2007 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- The effect of treatment with fenofibrate on the risk profile of patients with metabolic syndrome and mixed dyslipidemia treated on an outpatient basis2007 | Faculty of Medicine in Pilsen
- The effect of treatment with fenofibrate on the risk profile of patients with metabolic syndrome and mixed dyslipidemia treated on an outpatient basis2007 | First Faculty of Medicine
- Residual vascular risk and the global R3I (Residual risk reduction initiative)2010 | Central Library of Charles University
- Residual vascular risk and the global R3I (Residual risk reduction initiative)2010 | Faculty of Medicine in Pilsen
- A patient with high cardiovascular risk from the view of Czech Institute of Metabolic Syndrome2007 | Faculty of Medicine in Pilsen
- A patient with high cardiovascular risk from the view of Czech Institute of metabolic syndrome2007 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- A comparison of generic and semigeneric atorvastatin effectivity2005 | First Faculty of Medicine
- Obesity as a disease. First share. Etiology and pathogenesis, consequences and associated diseases, prevention and therapy2011 | Second Faculty of Medicine
- The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitus2012 | First Faculty of Medicine
- Combination therapy for dyslipidemia2014 | First Faculty of Medicine
- Combined hypolipidemic therapy using statins and fibrates reducing the cardiovascular risk in the patients with atherogenic dyslipidemia2010 | Faculty of Medicine in Hradec Králové
- Extermination of atherosclerosis not only in lower extremities2019 | Second Faculty of Medicine
- Individualized approach in dyslipidemia treatment2015 | Faculty of Medicine in Pilsen
- Status of fibrates in the treatment of patients with high CV risk: the European consensus in 20152016 | First Faculty of Medicine
- Familial dysbetalipoproteinemia: known unknown2022 | First Faculty of Medicine
- Combination hypolipidemic therapy2014 | First Faculty of Medicine
- Acute myocardial infarction in a male patient with metabolic syndrome and obstructive sleep apnea syndrome2020 | Faculty of Medicine in Pilsen
- What should not be done and why - cardiovascular prevention in the light of the latest recommendations2017 | First Faculty of Medicine
- On the liver and atherosclerosis2019 | Second Faculty of Medicine
- Evolocumab, proproteine convertase subtilisin/kexin type 9 inhibitor for intensive treatment of dyslipidemia2016 | Faculty of Medicine in Pilsen
- Genetic risk score in patients with the APOE2/E2 genotype as a predictor of familial dysbetalipoproteinemia2023 | First Faculty of Medicine, Faculty of Science